Masakazu Toi (Kyoto University Hospital, Kyoto, Japan) presented the results of the randomised, phase 3 POTENT trial. 1959 patients with hormone receptor-positive, HER2-negative, stage I–III primary breast cancer at intermediate or high risk of recurrence were randomly assigned (1:1) after surgery to standard adjuvant endocrine therapy alone (control) or with oral S-1 (80 mg, 100 mg, or 120 mg per day). At a median follow-up of 51·4 months, invasive disease-free survival (primary endpoint) was improved in the S-1 group (99 events) versus the control group (153 events; hazard ratio 0·63, 95% CI 0·49–0·81; p=0·0003). The trial was terminated early because the primary endpoint was met at this interim analysis. S-1 was well tolerated, with adverse events consistent with the known safety profile of S-1.

中文翻译：

---

圣安东尼奥乳腺癌专题讨论会2019。

Masakazu Toi（日本京都大学医院）介绍了这项随机的3期POTENT试验的结果。1959年患有激素受体阳性，HER2阴性，I–III期复发，中度或高复发风险的原发性乳腺癌患者在手术后被随机分配（1：1）接受标准辅助内分泌治疗（对照）或口服S- 1（每天80 mg，100 mg或120 mg）。在中位随访51·4个月时，与对照组相比，S-1组（99事件）的无创生存（主要终点）有所改善（153事件；危险比0·63，95％CI） 0·49-0·81； p = 0·0003）。该试验提前终止，因为在此中期分析中达到了主要终点。S-1的耐受性良好，不良事件与S-1的已知安全性一致。